AI-Technology and Services
We drive innovation & efficiency wherever pathology hits your drug development workflow.
Transforming Cancer Research & Development
Paige’s AI off-the shelf modules enable breakthroughs at every stage of cancer:
Diagnose – AI-assisted diagnostic applications for detecting, grading, and quantifying cancer in prostate, breast, colon, and 40+ cancer types
Screen – Detect 1,600+ biomarkers from H&E alone with OmniScreen™
Prognose – Compute Minimal Residual Disease (MRD), Residual Cancer Burden (RCB), and pathological Complete Response (pCR)
Predict Response – Enhance predictive power for CIN, HER2Complete, Lung IO response, FGFR, and cellular analytics
Research – Utilize Virchow and PRISM foundation models to advance precision oncology
Revolutionizing Drug Discovery & Clinical Trials with AI
Paige accelerates drug development, clinical trial efficiency, and biomarker discovery through advanced AI-powered analysis. By identifying critical biomarkers, matching patient subpopulations with targeted therapies, and repurposing existing drugs for new indications, our technology transforms the way cancer is understood and treated.
Foundational Model Suites
Paige’s Foundation Models handle complex cancer data at scale. Our Virchow and PRISM model suites efficiently characterize whole-slide images, detect cancer across 40+ tissue types, predict biomarkers, and provide pathology insights—all while minimizing training data requirements.
Our AI models leverage multi-modal capabilities, combining Large Vision Models (LVMs) with Large Language Models (LLMs) to:
Generate clinical reports
Detect cancer subtypes
Predict genomic biomarkers with minimal data
Zero-shot detection
By licensing Paige’s Foundation Models, organizations can reduce costs and shorten development timelines, deliver enhanced model performance and ensure regulatory compliance and governance.
AI Modules: Pre-Built, Scalable, and Highly Specialized
Paige’s AI modules provide ready-to-use solutions that support clinical applications, therapeutic targeting, biomarker discovery, and optimized trial design.
PanCancer Detection
Detects and localizes invasive cancer and precursors across 50+ H&E-stained tissue types
Digital Biomarker Panels
OmniScreen™, the first-of-its-kind digital biomarker application, predicts genomic alterations in 491 genes across multiple cancers
Why Partner with Paige?
Paige is redefining the future of oncology with unparalleled AI technology, regulatory excellence, and a global network of trusted partners. Our end-to-end solutions empower organizations to seamlessly integrate AI into research, diagnostics, and drug development, unlocking new possibilities for precision medicine.
Unmatched AI & Data Expertise
25M+ pathology slides from world-renowned cancer centers, creating the most comprehensive AI training dataset in oncology.
First-in-industry million-slide foundation model, published in Nature Medicine, developed in partnership with Microsoft.
Cutting-edge multi-modal AI models, combining vision and language for powerful insights.
Clinical-Grade AI Development & Validation
Experts in clinical-grade AI development, ensuring robust data governance, security, and compliance.
ISO 13485 & ISO 27001 certified, HIPAA, GDPR, and GxP compliant.
Seamless global AI deployment, validated in oncology trials worldwide.
Regulatory Leadership & Market Access
First FDA-cleared AI algorithm in digital pathology, with 12 CE-IVD and UKCA marks.
Proven track record in navigating complex AI regulations for global market access.
Expanding commercial footprint through partnerships with leading reference labs, CROs, and platform providers.
Paige provides a comprehensive AI ecosystem, ensuring innovation moves from development to deployment with confidence. Whether you're looking to enhance clinical decision-making, accelerate trials, or unlock new R&D, Paige delivers the AI solutions you need to lead in precision medicine.